Please use this identifier to cite or link to this item: http://www.repositorio.ufc.br/handle/riufc/25130
Title in Portuguese: Efficacy, safety and tolerability of aripiprazole in bipolar disorder : an updated systematic review and meta-analysis of randomized controlled trials
Author: Li, Dian-Jeng
Tseng, Ping-Tao
Stubbs, Brendon
Chu, Che-Sheng
Chang, Han-Yung
Vieta, Eduard
Fornaro, Michele
Carvalho, Andre F.
Solmi, Marco
Veronese, Nicola
Chen, Tien-Yu
Chen, Yen-Wen
Lin, Pao-Yen
Chows, Philip Chik-keung
Keywords: Bipolar disorder
Transtorno Bipolar
Aripiprazol
Issue Date: Oct-2017
Publisher: Progress in Neuropsychopharmacology & Biological Psychiatry
Citation: LI, DIAN-JENG et al. Efficacy, safety and tolerability of aripiprazole in bipolar disorder : an updated systematic review and meta-analysis of randomized controlled trials. Progress in Neuro-Psychopharmacology & Biological Psychiatry, v. 79, p. 289-301, oct. 2017.
Abstract in Portuguese: Numerous studies have investigated aripiprazole as a treatment for bipolar disorder (BD). therefore we conducted this comprehensive meta-analysis to investigate the efficacy and safety profile of aripiprazole in treating BD. Two authors conducted systematic searches of PubMed and ScienceDirect from inception until May 14th, 2017. Randomized controlled trials (RCTs) of people with BD who received aripiprazole were included. A total of 20 RCTs met the eligibility criteria, including two which investigated the efficacy of aripiprazole versus haloperidol (aripiprazole =340; haloperidol =337), three which compared aripiprazole versus lithium (aripiprazole =208; lithium =212), and 15 with multiple comparisons of aripiprazole versus a placebo (aripiprazole =1923; placebo =1499). Compared to a placebo, aripiprazole improved acute mania (Hedges' g: −0.299, p=0.001) and psychosis (Hedges' g: −0.296, p < 0.001) in the acute mania state, but did not improve depressive symptoms (Hedges' g: −0.127, p =0.054) in the acute depressive state. Aripiprazole was associated with lower relapse rates in bipolar mania when used in combination versus a placebo in maintenance therapy (odds ratio: 0.522, p < 0.029). Aripiprazole was also associated with higher levels of high density lipoprotein, lower dropout rates, but no difference in extrapyramidal symptoms in the maintenance phase versus a placebo or in comparison with other medications (haloperidol or lithium). Our results suggest that aripiprazole is effective and safe in treating bipolar mania. Further trials are necessary to evaluate the efficacy and tolerability versus other medications.
URI: http://www.repositorio.ufc.br/handle/riufc/25130
metadata.dc.type: Artigo de Periódico
ISSN: 0278-5846
Appears in Collections:DMC - Artigos publicados em revistas científicas

Files in This Item:
File Description SizeFormat 
2017_art_djli.pdf1,01 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.